Return to Contents in this Issue



Consensus Statement on the Diagnosis, Management, and Treatment of Angioedema Mediated by Bradykinin. Part II. Treatment, Follow-up, and Special Situations


Spanish Study Group on Bradykinin-Induced Angioedema (SGBA) (Grupo Español de Estudio del Angioedema mediado por Bradicinina: GEAB) T Caballero,1* ML Baeza,2,3# R Cabañas,1# A Campos,4# S Cimbollek,5# C Gómez-Traseira,1# T González Quevedo,5# M Guilarte,6# J Jurado-Palomo,7# JI Larco,1# MC López-Serrano,1# M López-Trascasa,1,8 C Marcos,9# JM Muñoz-
Caro,1 M Pedrosa,1# N Prior,1# M Rubio,2# A Sala-Cunill 6#

*Coordinator of the SGBA/GEAB
#Members of the SGBA/GEAB in alphabetical order
1Servicio de Alergia, Hospital La Paz Health Research Institute (IdiPaz), Madrid, Spain
2Gregorio Marañón General University Hospital, Madrid, Spain
3Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)-U761
4La Fe University Hospital, Valencia, Spain
5Virgen del Rocío University Hospital, Sevilla, Spain
6Vall d’Hebron University Hospital, Barcelona, Spain
7Nuestra Señora del Prado General Hospital, Talavera de la Reina, Toledo, Spain
8Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)-U754
9Vigo University Hospital Complex, Vigo, Spain

J Investig Allergol Clin Immunol 2011; Vol. 21(6): 422-441



Background: There are no previous Spanish guidelines or consensus statements on bradykinin-induced angioedema.

Aim: To draft a consensus statement on the management and treatment of angioedema mediated by bradykinin in light of currently available scientific evidence and the experience of experts. This statement will serve as a guideline to health professionals.

Methods: The consensus was led by the Spanish Study Group on Bradykinin-Induced Angioedema, a working group of the Spanish Society of Allergology and Clinical Immunology. A review was conducted of scientific papers on different types of bradykinin-induced angioedema (hereditary and acquired angioedema due to C1 inhibitor defi ciency, hereditary angioedema related to estrogens, angioedema induced by
angiotensin-converting enzyme inhibitors). Several discussion meetings were held to reach the consensus.

Results: Treatment approaches are discussed, and the consensus reached is described. Specifi c situations are addressed, namely, pregnancy, contraception, travelling, blood donation, and organ transplantation.

Conclusions: A review of and consensus on treatment of bradykinin-induced angioedema is presented.

Key words: Angioedema. C1-inhibitor. Bradykinin. Estrogens. ACE inhibitors.